Tradestie Institutional Equity Comparison Engine

RDY vs IFN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RDY Overall Edge

RDY Captures Institutional Edge (3โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Dr. Reddy's Laboratories Limited American Depositary Shares (RDY) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, RDY trades at 31.6x Forward P/E with 9.1% operating margin (-1.5% YoY revenue) versus IFN at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, RDY sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against IFN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner RDY
RDY 31.6x vs IFN N/M Fwd P/E
Growth & Margin Winner RDY
Op Margin 9.1% vs N/A ยท YoY -1.5% vs N/A
Momentum & Technical Winner RDY
1Y +6.0% vs -23.9% ยท 52W Pos 78% vs 26%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
RDY NYSE
Dr. Reddy's Laboratories Limited American Depositary Shares
Pharmaceutical Preparations
$14.70
-0.27% 1D
Market Cap $12.3B
1M Return +12.47%
1Y Return +5.98%
Forward P/E 31.6x
Unified AI Score
34.7 / 100 SELL
Tech 17.0 Fund 34.0 Flow 50.0 Mom 40.0
IFN NYSE
The India Fund, Inc.
Institutional Equity
$11.48
+0.17% 1D
Market Cap $593.5M
1M Return +8.61%
1Y Return -23.92%
Forward P/E N/M
Unified AI Score
29.1 / 100 SELL
Tech 5.0 Fund 33.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RDY +5.98% IFN -23.92% Spread: +29.9 pp (RDY Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
RDY TTM Op. Margin: 9.1% IFN TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RDY vs IFN. Trailing 12-month operating profitability (RDY 9.1% vs IFN N/A) and valuation multiples (RDY 31.6x vs IFN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RDY (9) vs IFN (1)
Institutional Metric RDY IFN Criterion Row Winner
Market Capitalization Scale $12.3B $593.5M Larger Scale RDY
Trailing P/E Ratio Valuation 40.9x N/M Lower Multiple RDY
Forward P/E Ratio Valuation 31.6x N/M Lower Multiple RDY
Revenue Growth (YoY) Growth -1.5% N/A Higher Growth RDY
Operating Margin (TTM) Profitability 9.1% N/A Higher Margin RDY
Net Profit Margin Profitability 8.5% N/A Higher Margin RDY
Return on Equity (ROE) Capital Efficiency 7.3% N/A Higher ROE RDY
52-Week Range Position Momentum 78% ($11โ€“$16) 26% ($10โ€“$15) Stronger Trend RDY
Beta / 30D Volatility Risk Regime 0.39ฮฒ ยท 24% Vol 0.68ฮฒ ยท 20% Vol Lower Realized Risk IFN
Unified Institutional Score Composite Signal 34.7 / 100 (SELL) 29.1 / 100 (SELL) Higher Composite RDY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RDY vs IFN Buy Guide
RDY UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live RDY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IFN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live IFN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RDY nor IFN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.